Clinical Trials List
Protocol NumberMK-3475-04C
Active
2024-06-01 - 2030-12-31
Phase I/II
Recruiting2
ICD-10C67.9
Malignant neoplasm of bladder, unspecified
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9188.9
Malignant neoplasm of bladder, part unspecified
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Yuh-Shyan Tsai 無
- 鍾秉軒 無
- Jiann-Hui Ou 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
15 participants
-
Global
98 participants
